Health Trials

About this trial

This prospective observational study aims to investigate subtype-specific circulating microRNAs (miRNAs) and their association with response to neoadjuvant chemotherapy (NAC) in patients with breast cancer. Serum samples will be collected before NAC and prior to surgery, and changes in miRNA expression levels will be evaluated. Pathological complete response (pCR) and Miller-Payne scoring will be used to assess treatment response after NAC. The study also explores whether changes in circulating miRNA profiles can predict treatment response across different breast cancer subtypes. The findings may help identify biomarkers that support treatment planning and personalized therapy strategies.

Eligibility criteria

Qualifiers

Histologically confirmed breast cancer

Planned to receive neoadjuvant chemotherapy

Biologically female

Age ≥ 18 years

Disqualifiers

Presence of metastatic disease at diagnosis

Prior systemic chemotherapy for breast cancer

Pregnancy or breastfeeding

Active infection or uncontrolled comorbid conditions interfering with study participation

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

80 Participants
are grouped into 1 trial group

Locations

1
Istanbul Atlas University Faculty of Medicine Istanbul Turkey (Türkiye)

Sponsors and collaborators

Atlas University

Lead sponsor

Source ClinicalTrials.gov